Best Dividend Stocks To Watch For 2018

When it comes to safe stocks, there may be none safer than healthcare conglomerate Johnson & Johnson (NYSE:JNJ). Johnson & Johnson is often a staple holding for income seekers, conservative investors, and even value investors. It has a 54-year streak of increasing its dividend payout, which should almost certainly become 55 years come April, and it’s one of two remaining publicly listed companies with a “AAA” credit rating from Standard & Poor’s. That’s a higher credit rating than the U.S. government.

The secret to J&J’s long-term success has been its business structure. Instead of operating as one giant company, it’s composed of more than 250 subsidiaries, which allows management to play with the dominoes, if you will, from time to time, in order to boost growth. It’s been able to divest slower-growing assets and acquire pharmaceutical products in recent years to boost its near- and intermediate-term growth prospects. Pharma is, without question, the largest contributor to its gross margin and top- and bottom-line growth.

Best Dividend Stocks To Watch For 2018: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed most recently at $36.18, with a consensus price target of $57.38 and a 52-week range of $15.97 to $40.65.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Jim Robertson]

    Small cap clinical-stage biopharmaceutical stock Aimmune Therapeutics (NASDAQ: AIMT) is aclinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The Companys Characterized Oral Desensitization ImmunoTherapy (CODIT) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune Therapeutics first investigational biologic product using CODIT⒙is AR101 for the treatment of peanut allergy.AR101 has received the FDAs Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials where enrollment was announced last month.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.13, with a consensus price target of $55.50 and a 52-week range of $15.97 to $40.65.

Best Dividend Stocks To Watch For 2018: Carnival Corporation(CCL)

Advisors’ Opinion:

  • [By Chris Lange]

    Carnival Corp. (NYSE: CCL) fiscal first-quarter report is scheduled for Thursday. The consensus forecast is $0.43 in EPS on $4.11 billion in revenue. Shares closed at $66.91 apiece. The consensus price target is $76.94, and the 52-week range is $57.09 to $72.70.

  • [By Rick Munarriz]

    Carnival Corporation & plc (NYSE:CCL) (NYSE:CUK)shareholders have to be feeling pretty good these days. The stock hit yet another new high on Friday, and the stock is trading 13% higher so far in 2017.It’s been smooth sailing so far this year, but the first big test comes on Tuesday morning when the world’s largest cruise line operator reports financial results for its fiscal first quarter.

  • [By WWW.THESTREET.COM]

    How about individual stories? Tuesday I was pleasantly surprised by the commentary on both the Darden (DRI) and Carnival (CCL) calls. Weekend dining and lunch were very strong for Darden, parent of Olive Garden, even though CEO Gene Lee acknowledged that it’s competing against “new necessities today, whether smartphones, whether it’s your cable bill, your Netflix bill. I mean, they have increased significantly over the years.” Hmm, is there any wonder why takeout pizza is so strong? Makes me want to buy both Darden and Domino’s (DPZ) .

Best Dividend Stocks To Watch For 2018: InspireMD, Inc.(NSPR)

Advisors’ Opinion:

  • [By Lisa Levin]

    InspireMD Inc (NYSE: NSPR) was down, falling around 35 percent to $1.29. InspireMD reported the pricing of public offering of up to $7.5 million.

    Commodities